Conduit Pharmaceuticals Inc. announced that it presented a compliance plan to Nasdaq regarding its listing rules, specifically seeking an extension to comply with minimum bid price and market value ...
Conduit Pharmaceuticals Inc., currently valued at $1.28 million and showing a weak financial health score according to InvestingPro analysis, has been granted an extension by The Nasdaq Stock Market ...
Cizzle Biotechnology Holdings plc, the UK based diagnostics developer, announces a further update regarding the Company's put option to sell its 5% economic interest and royalty sharing agreement in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback